Original Article

OPEN ACCESS: Patient Retention in a Substance Use Disorder Telemedicine Clinic

Authors: Justine F. Maxwell, MPH, DrPH, Sue S. Feldman, RN, PhD, Li Li, MD, PhD

Abstract

Objectives: Although research has continued to show that substance use disorders (SUDs) can be treated effectively with evidence-based treatment, there continues to be gaps in access, and utilization remains low. Alternative SUD treatment methods, including telemedicine, are increasingly being explored to reach patients where traditional in-person treatment approaches are inaccessible. This cross-sectional study aimed to explore SUD treatment retention, specifically comparing telemedicine-delivered opioid use disorder (OUD) treatment with a traditional in-person treatment delivery approach.

Methods: Patients at Cahaba Medical Care, an FQHC in Birmingham, AL with a diagnosis of OUD and undergoing buprenorphine/naloxone or buprenorphine treatment were categorized into two groups: treatment and control. The dependent variable, retention to SUD treatment, was assessed at four different time periods over 12 months to determine patient SUD consultation appointment attendance. Multiple linear regression was used to examine the relationship between SUD treatment retention and delivery mode. Correlations were obtained to assess associations between frequency of urine drug screens performed and SUD treatment retention.

Results: As the number of the urine drug screens patients received increased by 1, the number of SUD treatment program consultations patients attended increased by 0.69 (P < 0.001). There was no significant difference in SUD treatment retention between traditional in-person and telemedicine delivered approaches, however.

Conclusions: The findings of this study suggest that a telemedicine-delivered treatment program equals retention effectiveness when compared with in-person delivery. This suggests that leveraging telemedicine to treat patients with SUD could be an effective alternative for those unable to access treatment or who are less likely to attend or complete traditional in-person treatment sessions.

Full Article

Having trouble viewing the article content below? Click here to open it directly.

Images

Download Image

Download Image

References

1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Substance use disorders. https://www.cdc.gov/drugoverdose/featured-topics/substance-use-disorders/index.html. Published October 5, 2022. Accessed November 6, 2023.
 
2. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Addiction medicine primer. https://www.cdc.gov/overdose-prevention/hcp/toolkits/addiction-medicine.html?CDC_AAref_Val=https://www.cdc.gov/opioids/addiction-medicine/primer.html. Published March 2, 2022. Accessed November 6, 2023.
 
3. Substance Abuse and Mental Health Services Administration. Medications for substance use disorders. https://www.samhsa.gov/medication-assisted-treatment. Accessed November 6, 2023.
 
4. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2020 National Survey of Drug Use and Health (NSDUH) releases. https://www.samhsa.gov/data/release/2020-national-survey-drug-use-and-health-nsduh-releases. Published 2021. Accessed November 6, 2023.
 
5. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2021 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/reports/rpt39443/2021NSDUHFFRRev010323.pdf. Published 2022. Accessed November 6, 2023.
 
6. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. 2021 National Survey on Drug Use and Health: model-based estimated totals (in thousands) (50 states and the District of Columbia). https://www.samhsa.gov/data/sites/default/files/reports/rpt39466/2021NSDUHsaeTotals121522/2021NSDUHsaeTotals121522.pdf. Accessed November 6, 2023.
 
7. Lin LA, Casteel D, Shigekawa E, et al. Telemedicine-delivered treatment interventions for substance use disorders: a systematic review. J Subst Abuse Treat 2019;101:38–49.
 
8. Eibl JK, Gauthier G, Pellegrini D, et al. The effectiveness of telemedicine-delivered opioid agonist therapy in a supervised clinical setting. Drug Alcohol Depend 2017;176:133–138.
 
9. Jones CM, Shoff C, Hodges K, et al. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and furing the COVID-19 pandemic. JAMA Psychiatry 2022;79:981–992.
 
10. Weintraub E, Greenblatt AD, Chang J, et al. Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. Am J Addict 2018;27: 612–617.
 
11. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend 2019;197:78–82.